Cargando…

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor against the SARS-CoV-2 protease 3CL(pro) that has been licensed for clinical use. To identify mutations that confer resistance to this protease inhibitor, we engineered a chimeric vesicular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heilmann, Emmanuel, Costacurta, Francesco, Moghadasi, Seyed Arad, Ye, Chengjin, Pavan, Matteo, Bassani, Davide, Volland, Andre, Ascher, Claudia, Weiss, Alexander Kurt Hermann, Bante, David, Harris, Reuben S., Moro, Stefano, Rupp, Bernhard, Martinez-Sobrido, Luis, von Laer, Dorothee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765458/ https://www.ncbi.nlm.nih.gov/pubmed/36194133 http://dx.doi.org/10.1126/scitranslmed.abq7360

Ejemplares similares

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system
por: Costacurta, Francesco, et al.
Publicado: (2023)

Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
por: Paciaroni, Alessandro, et al.
Publicado: (2023)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
por: Gidari, Anna, et al.
Publicado: (2022)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
por: Ip, Jonathan Daniel, et al.
Publicado: (2023)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Crystallization of Feline Coronavirus M(pro) With GC376 Reveals Mechanism of Inhibition
por: Lu, Jimmy, et al.
Publicado: (2022)

Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376
por: Luan, Xiao-dong, et al.
Publicado: (2022)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis
por: Sharun, Khan, et al.
Publicado: (2020)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Author Correction: Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376
por: Luan, Xiao-dong, et al.
Publicado: (2022)

Interaction of GC376, a SARS-COV-2 M(PRO) inhibitor, with model lipid membranes
por: Klacsová, Mária, et al.
Publicado: (2022)

A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection
por: Chen, Yongkang, et al.
Publicado: (2023)

MINOS: Bt 376 - 599 ext - 376 ext - AP (100)
Publicado: (1991)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
por: Tober, R, et al.
Publicado: (2012)

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020)

Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions
por: Wang, Yining, et al.
Publicado: (2022)

Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants
por: Volland, André, et al.
Publicado: (2021)

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir
por: Kawajiri, Takahiro, et al.
Publicado: (2023)

Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376
por: Ye, Gang, et al.
Publicado: (2020)

Travaux au bâtiment 376
Publicado: (1992)

Studies on antiviral resistant SARS-CoV-2 Mpro mutants
por: Esler, Morgan A., et al.
Publicado: (2023)

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
por: Hu, Yanmei, et al.
Publicado: (2020)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract
por: Shi, Yuejun, et al.
Publicado: (2021)

Effect of GS-441524 in combination with the 3C-like protease inhibitor GC376 on the treatment of naturally transmitted feline infectious peritonitis
por: Lv, Jinbao, et al.
Publicado: (2022)

The Remarkable Selectivity of Nirmatrelvir
por: Duveau, Damien Y., et al.
Publicado: (2022)

Facade repair works on building 376
Publicado: (2003)

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
por: Kawashima, Sho, et al.
Publicado: (2023)

Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
por: Yang, Yujian, et al.
Publicado: (2023)

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
por: Schreiber, Liesa-Marie, et al.
Publicado: (2019)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

Rapid resistance profiling of SARS-CoV-2 protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

Rapid resistance profiling of SARS-CoV-2 protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hupb09h3e8fu6q33stv3gsamql